Clinical trials: Healthy Male Volunteers
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers
This study is an open label, randomized, three-way crossover study to assess the effect of particle size on the PK and safety of single inhaled doses of AZD7594 in healthy subjects (males aged 18 to 55 years [inclusive]).
- Trial name
- NCT02928354
- Testing
- Treatment A - AZD7594, Treatment B - AZD7594, Treatment C - AZD7594
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Trypanosomiasis, African
Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation
Phase 1 bioequivalence (BE) study. This study is for regulatory purpose to determine BE of the tablet formulation used in the clinical trials and the final marketed tablet formulation under fed condition.
- Trial name
- NCT02571062
- Testing
- Fexinidazole
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Healthy Vollunteer
Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions
Objectives: To determine and compare the rate and extent of absorption of a test formulation with that of a reference innovator formulation when given as equal labeled dose after multiple oral dose administration in healthy…
- Trial name
- BE24-005 (NCT06316336)
- Testing
- Alfuzosin Hydrochloride 10 mg, Xatral® XL 10 mg
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pharma Nueva
Healthy Male Volunteer
A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers
Study Design : randomized, open label, single-dose, 2-way cross-over design Phase : Phase I
- Trial name
- NCT01776047
- Testing
- Exforge®, G-0081
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Healthy Volunteer
A Phase 1 Study of Mosliciguat in Healthy, Adult Males
This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.
- Trial name
- NCT07185321
- Testing
- Mosliciguat, 14C mosliciguat, Dry Powder Inhaler
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pulmovant, Inc.
Nephrotic Syndrome, Lipodystrophy
Effects of Meal Macronutrients on Postprandial Lipids
Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood.
- Conditions
- Nephrotic Syndrome, Lipodystrophy, Metabolic Syndrome, Healthy Volunteer
- Trial name
- NCT07313787
- Testing
- High carb then high fat breakfast, High fat then high carb breakfast
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy Volunteer
A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants
The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.
- Trial name
- NCT06953934
- Testing
- ABBV-932
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181
To investigate the safety, tolerability, pharmacokinetics (including dose proportionality assessment), and pharmacodynamics of single rising oral doses of BI 1181181 (Single rising dose (SRD) part) Secondly, to investigate the…
- Trial name
- NCT02044406
- Testing
- BI 1181181, BI 1181181, R, BI 1181181, T2
- Where
- Germany
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
SAD Study to Assess the Safety, Tolerability, PK, and In-Vivo Performance of AMT-126 in Healthy Male and Female Subjects
Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of AMT-126 and Optional Pharmacoscintigraphic Assessment of Oral AMT-126
- Trial name
- NCT05476107
- Testing
- AMT-126, Radioactive Tablet (Part 2 Only)
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Applied Molecular Transport
Chronic Kidney Disease, Healthy Volunteers
A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD). The kidneys filter extra water and waste out of the blood and make urine.
- Trial name
- NCT05800444
- Testing
- BAY3283142
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
None (i.e. Healthy Volunteers)
Levomilnacipran in Healthy Males
Levomilnacipran is an antidepressant currently approved in Canada to treat Major Depressive Disorder (MDD). Thirty-six healthy male participants will receive escalating doses of levomilnacipran, duloxetine, or placebo every 7…
- Trial name
- NCT03249311
- Testing
- Levomilnacipran, Duloxetine
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Healthy Subjects
Bioequivalence Study of SB797620 in Healthy Japanese Volunteers
This study will test whether the Drug levels in plasma after combination formulation tablet dosing (SB797620) and separate formulation tablets dosing (rosiglitazone and glimepiride) to Japanese Healthy volunteer would be the same…
- Trial name
- NCT00549263
- Testing
- SB797620
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Adult Participants, Diabetic Kidney Disease
Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439…
- Trial name
- NCT07473323
- Testing
- MTX-439
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Mediar Therapeutics
Healthy Volunteer
Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961
This study is a Phase 1, open-label, non-randomized, 2-period, fixed sequence study to characterize the metabolic profile and routes of excretion of oral [14C]PF-06882961 and to evaluate the absolute oral bioavailability of…
- Trial name
- NCT04495140
- Testing
- [14C]PF-06882961, 50 mg, PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
- Where
- 2 sites in Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient
The purpose of this study is to measure two different formulations of BG00012 to determine how much of each formulation of BG00012 reaches the blood stream and how long it takes the body to get rid of it, when given as a single…
- Trial name
- NCT01069913
- Testing
- BG00012
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy
Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers
The objective of the present study is to obtain information about the safety and tolerability of BIIX 1 XX, to determine the pharmacologically active dose (range) by performing a methacholine challenge test and to obtain…
- Trial name
- NCT02199873
- Testing
- BIIX 1 XX - single rising dose
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatitis B, Chronic
A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic…
- Trial name
- NCT02956850
- Testing
- RO7020531
- Where
- 18 sites in Bulgaria, Hong Kong and 6 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Volunteer
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
This is a single-center, open label, multiple dose study to investigate the pharmacokinetics of RG1662 given twice daily over 28 days, and in addition, the excretion and metabolism of [13C]-labeled IV microdoses and an oral…
- Trial name
- NCT01684891
- Testing
- RG1662
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers, Pharmacologic Action
A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate
This study is a single-center, open-label, 3-group, fixed-sequence drug-drug interaction study to assess the effect of coadministration of multiple-dose itraconazole or diltiazem on the single-dose PK of AZD3293 and the effects…
- Trial name
- AZD3293DDI (NCT02010970)
- Testing
- Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
CKD-397 Drug-drug Interaction Study (A)
The purpose of this study is to investigate to effect of tamsulosin on the pharmacokinetic properties of tadalafil
- Trial name
- CKD-397DDI(A) (NCT02247518)
- Testing
- Cialis Tab. 5mg, Harnal-D Cap. 0.2mg
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.